HOT SIZZLING NEWS – Valeant Pharmaceuticals International, Inc. (NYSE:VRX)

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) stock price declined -3.51% at $12.92. Its total market capitalization is $4.50B. Its day lowest price was $12.89 and its hit its day highest price at $13.45. The stock recent volume is 14.13 million shares in comparison to its usual trading volume of 11.77 million shares.

Looking at the stock’s price progress on the past 52-week graph, VRX recorded a 52-week high of $24.30 and it is now trading -46.83% away that level. The stock is trading by +55.46% to its 52-week low of $8.31.

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) (“Valeant”) announced the results to date of the pending cash tender offers (the “Tender Offers”) by Valeant and Valeant Pharmaceuticals International (“VPI,” and together with Valeant, the “Offerors”), a wholly-owned subsidiary of Valeant, to purchase up to $1,000,000,000 aggregate principal amount (the “Aggregate Maximum Purchase Amount”) of their respective outstanding notes listed in the table below (collectively, the “Notes”), as well as the anticipated early settlement date for the Tender Offers on October 17, 2017 (the “Early Settlement Date”). Valeant is the Offeror for the notes issued by it, and VPI is the Offeror for the notes issued by it.

All terms and conditions of the Tender Offers remain unchanged as set forth in the Offer to Purchase dated October 2, 2017 (the “Offer to Purchase”) and the related Letter of Transmittal, and capitalized terms used but not defined herein shall have the meaning ascribed to them in the Offer to Purchase.

Valeant Pharmaceuticals International, Inc. operates as a pharmaceutical and medical device company worldwide. It operates in three segments: Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products. The company offers Lotemax gel for the treatment of inflammation and pain following ocular surgery; Ocuvite, a lutein eye vitamin and mineral supplement; PreserVision, an antioxidant eye vitamin and mineral supplement; ReNu Multiplus products; Biotrue multi-purpose solution for healthy contact lens wear; Artelac to treat dry eyes; Boston, a cleansing solution for gas permeable contact lenses; and Bedoyecta, a vitamin B complex. It also provides SofLens daily disposable contact lenses; ophthalmic surgical products; PureVision, a silicone hydrogel; Biotrue ONEday daily disposable contact lenses; Bausch + Lomb Ultra, a silicone hydrogel replacement contact lens; and medical device systems. In addition, the company offers Xifaxan for the treatment of irritable bowel syndrome; Provenge for the treatment of prostate cancer; Uceris to get ulcerative colitis under control; Arestin, a subgingival sustained-release antibiotic; Jublia for the treatment of onychomycosis; Solodyn for the treatment of acne; Elidel to treat skin conditions; and Glumetza tablets to enhance glycemic control. Further, it provides Wellbutrin XL for the treatment of major depressive disorder; Isuprel injections; Xenazine for the treatment of chorea; Nitropress for the reduction of blood pressure of patients in hypertensive crises; Cuprimine to treat Wilson’s disease; Zegerid to treat certain stomach and esophagus problems; Tobramycin and Dexamethasone ophthalmic suspension for steroid responsive inflammatory ocular conditions; and Latanoprost medicines to treat a type of glaucoma. The company was formerly known as Biovail Corporation and changed its name to Valeant Pharmaceuticals International, Inc. in September 2010. The company was founded in 1983 and is headquartered in Laval, Canada.

David Brinkley

David Brinkley gives coverage to fashion Section of the website. He enjoys and appreciates engaging with like-minded individuals that inspire him to think beyond what is generally accepted. He has a fashion designing degree from the University of California, Berkeley. Connect to David davidbrinkley@usstockjournal.com